论文部分内容阅读
目的:探索直接抗病毒药(DAAs)对慢性丙型肝炎患者外周血单个核细胞频率及其活化因子sCD14s、CD163的影响。方法:收集初治慢性丙型肝炎患者15例，健康对照者10名资料；慢性丙型肝炎患者给予DAAs治疗12周，分别在第0、4、12周收取血标本，健康对照者血标本作为对照。流式细胞术检测外周血经典型CD14n ++CD16n -单个核细胞和促炎型CD14n +CD16n +单个核细胞频率，用酶联免疫吸附法检测血清sCD14s、sCD163。计量资料两组间比较采用n t检验，多组间比较先行方差分析，进一步两两比较，用LSD-n t检验。n 结果:DAAs治疗前外周血CD14n +CD16n +单个核细胞频率(18.49%±1.54%比10.65%±0.83%)、血清sCD14s[ (64 407.38±5 778.49）pg/ml比（28 370.76±2 357.68）pg/ml]和sCD163[（22 853.80±4 137.61）pg/ml比（2 934.41±223.31）pg/ml）]均高于健康对照者（n P < 0.05），而外周血CD14 n ++CD16n -单个核细胞频率则低于健康对照者(59.14%±0.54%比72.75%±1.31%，n P 0.05)，血清sCD14和sCD163仍高于健康对照者[sCD14：（44 390.06±3 330.17） pg/ml比（28 370.76±2 357.68） pg/ml, n P < 0.01；sCD163:（11 494.79±1 836.97）pg/ml比（2 934.41±223.31） pg/ml， n P 0.05)。n 结论:DAAs治疗可降低慢性丙型肝炎患者外周血单个核细胞的活化。“,”Objective:To explore the effects of direct antiviral agent (DAAs) on the frequency of peripheral blood mononuclear cells and their activating factors sCD14s and CD163 in patients with chronic hepatitis C.Methods:Data of 15 treatment-naive chronic hepatitis C patients and 10 healthy controls were collected. Patients with chronic hepatitis C were treated with DAAs for 12 weeks. Blood samples were collected at 0, 4 and 12 weeks respectively, and blood samples of healthy controls were used as controls. Flow cytometry was used to detect the frequency of classical CD14n ++CD16n - mononuclear cells and pro-inflammatory CD14n +CD16n + mononuclear cells in peripheral blood. Serum sCD14s and sCD163 were detected by enzyme-linked immunosorbent assay. The comparison between the two groups was performed by t-test. The comparison between multiple groups was performed by analysis of variance, and further pairwise comparison was performed by LSD-t test.n Results:Prior DAAs treatment, peripheral blood CD14n +CD16n + mononuclear cell frequency (18.49% ± 1.54% vs. 10.65% ± 0.83%), serum sCD14s [(64 407.38 ± 5778.49) pg/ml vs. (28 370.76 ± 2 357.68 ) pg/ml] and sCD163 [(22 853.80 ± 4 137.61) pg/ml vs. (2 934.41 ± 223.31) pg/ml] were all higher than healthy controls (n P < 0.05), while the frequency of CD14 n ++CD16n - mononuclear cells in peripheral blood was lower than healthy controls (59.14%±0.54% vs. 72.75%±1.31%, n P 0.05), and serum sCD14 and scd163 were still higher than those of healthy controls [sCD14: (44 390.06 ± 3 330.17) pg / ml vs. (28 370.76 ± 2 357.68) pg/ml, Scd163: (11 494.79 ± 1 836.97) pg / ml vs. (2 934.41 ± 223.31) pg / ml, n P 0.05).n Conclusion:DAAs therapy can reduce the activation of peripheral blood mononuclear cells in patients with chronic hepatitis C.